CRISPR

Left: LinedanceAI co-founder Mohamed Elwazer; Center illustration: leonello/iStock; Right: Lantern Pharma CEO Panna Sharma

16 Biotech Companies in Dallas-Fort Worth ‘Putting the Tech in Bio’ to Drive Breakthroughs

by | Mar 1, 2023

Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem. Leaders in the industry attribute this success to the unique convergence of the region’s exceptional tech talent pool and cutting-edge developments in life science....

MORE►
Form Bio Spins Out of Colossal Bioscience to Offer Scientists the ‘Missing Piece’
by | Sep 27, 2022
Dallas-based Colossal Biosciences, the de-extinction company behind plans to bring back the woolly mammoth and thylacine, developed its own software solution "after reviewing everything available on the market." Now it's sharing the platform with the launch of Form Bio.

The spinout's technology tools can help drive the “entire molecular revolution” that is occurring in the life sciences and biotech space, in addition to bolstering the Lone Star state as a hub for the industry, says Chief Strategy Officer Claire Aldridge.
MORE►
Mammoth Project: Dallas’ Colossal Raises $60M to Advance Genetic Engineering and ‘De-Extinction’ Technologies
by | Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid. With a total raise of $75 million to date, the startup aims to have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►

[Image: Oleksandr Bushko/istockphoto]

UTSW Scientist: ‘We Need More Women Thinking Creatively in the Lab and Pushing Science Forward’

by | Oct 8, 2020
This year's Nobel Prize in Chemistry, awarded to two female scientists for the development of CRISPR as a gene-editing tool, is a revolution, according to a pair of UTSW scientists. UTSW's Eric Olson and Rhonda Bassel-Duby use the technology in their work to treat Duchenne muscular dystrophy. Olson also is the co-founder of biotech Exonics Therapeutics, which exited last year in a deal roughly valued at $1B.
MORE►
Discovery: UNTHSC Works on More Precise CRISPR, UTSW Uses AI in Depression Research
by | Oct 4, 2019
In this weekly roundup of research and development activity in North Texas, you’ll also find out about how a $427,000 NIH grant is helping a UTA team study the healing of cranial injuries, and how Lexus researchers are creating a high-end audio system.
MORE►
CRISPR CAS9 gene editing background
UT Southwestern-Linked Startup Exonics Therapeutics Exits in Deal Valued at $1B
by | Jun 17, 2019
The biotech company uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, and was co-founded by UTSW researcher and faculty member Eric Olson.
MORE►
research
R&D: UTA Scientist Seeks Best Rock to Block Nuclear Waste; Grant Enables PTSD Research
by | Sep 7, 2018
Also, you'll learn about advances to treat Duchenne muscular dystrophy and migraines. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2024 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners